Gala­pa­gos goes 0-for-3 on in­flam­ma­tion pro­gram as it cuts an ear­ly-stage can­di­date

Gala­pa­gos has cut an­ti-in­flam­ma­to­ry drug can­di­date GLPG4399 fol­low­ing the com­ple­tion of an ear­ly-stage healthy vol­un­teer tri­al, ac­cord­ing to its 2022 an­nu­al re­port re­leased Thurs­day af­ter­noon.

GLPG4399 was a SIK3 in­hibitor, one in a line of such salt-in­ducible ki­nase (SIK) in­hibitors that Gala­pa­gos has been try­ing to de­vel­op for in­flam­ma­to­ry dis­eases like rheuma­toid arthri­tis and ul­cer­a­tive col­i­tis. Orig­i­nal­ly, the biotech had been plan­ning to move the drug for­ward in a study with rheuma­toid arthri­tis pa­tients in the mid­dle of this year, but now it’s halt­ing the pro­gram and go­ing back to search for new SIK in­hibitors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER